TIDMEKF

EKF Diagnostics Holdings PLC

03 September 2015

EKF Diagnostics Holdings plc

("EKF", the "Company")

New tender wins for Hemo Control

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care, central laboratory and molecular diagnostics business, announces that it has recently won two new tenders for its Hemo Control point-of-care hemoglobin analyser.

In Turkey, EKF has been awarded a tender by the Red Crescent, the humanitarian organisation that runs the nation's blood banking service. Under the terms of the tender EKF will supply 668 Hemo Control analysers and 160,000 boxes of cuvettes over a three year period, in a contract worth a little under EUR1 million.

The second tender has been secured by EKF's US sales team from the State of Colorado's Women, Infants and Children programme. The tender to supply Hemo Control analysers (sold in the US as HemoPoint H2) and related cuvettes is valued at $450,000 over a five year period with additional incremental tenders expected for further analyser accessories.

Julian Baines, CEO of EKF Diagnostics said: "We are delighted to announce these two new business wins. The hemoglobin testing market is highly competitive and in winning both of these accounts we have demonstrated once again that we have a world-class product that can compete with the market leader. In addition, we anticipate that we will be able to announce further tender wins in the near future."

In accordance with Rule 26.1 of the Takeover Code, a copy of this announcement will be published on the Company's website http://www.ekfdiagnostics.com by no later than 12 noon on 3 September 2015.

Enquiries:

 
EKF Diagnostics Holdings plc                               Tel: 029 2071 0570 
David Evans, Executive Chairman                            Mob: 07740 084 452 
Julian Baines, CEO                                         Mob: 07788 420 859 
Paul Foulger, CFO                                          Mob: 07710 989 255 
Panmure Gordon (UK) Limited                                Tel: 020 7886 2500 
Robert Naylor (Corporate Finance) 
Paul Fincham (Corporate Finance) 
 
Walbrook PR Limited                  Tel: 020 7933 8780 or ekf@walbrookpr.com 
Paul McManus                                               Mob: 07980 541 893 
Lianne Cawthorne                                           Mob: 07584 391 303

About EKF Diagnostics Holdings plc - www.ekfdiagnostics.com

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for EUR14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in September 2010), Argutus Medical Limited (acquired in December 2010) and Stanbio Laboratory L.P. (acquired in June 2011). In 2013 EKF established a new subsidiary, EKF Molecular Diagnostics Ltd, to focus on molecular and companion diagnostics and acquired 360 Genomics Ltd, a business that owns diagnostics technologies for cancer gene detection.

The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focussing on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.

In March 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2.

In March 2014, EKF acquired Separation Technology, Inc., a Florida based manufacturer of in vitro diagnostics devices for the haematology testing market. In April 2014, EKF completed the acquisitions of Selah Genomics Inc., a US based developer of molecular diagnostics for personalised medicine and DiaSpect Medical AB., a Swedish based manufacturer of point-of-care haemoglobin analysers.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAPKBDQFBKDPCK

(END) Dow Jones Newswires

September 03, 2015 02:00 ET (06:00 GMT)

International Brand Licensing (LSE:IBL)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more International Brand Licensing Charts.
International Brand Licensing (LSE:IBL)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more International Brand Licensing Charts.